Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: AI
Millions of bottles of over-the-counter cooling eye drops have been recalled across the United States after the US Food and Drug Administration (FDA) raised concerns that the products may not be sterile. Sterility issues raises the risk of eye infections significantly.
The FDA has classified the recall as a Class II recall. An FDA Class II recall for a product refers to the public health action that may cause temporary health problems, where the chance of serious harm is remote.
This recall covers nearly 12 million bottles of eight Rohto cooling eye drop products. The agency said the recall was initiated on July 14, due to a “lack of assurance of sterility” in the affected products.
The eye drops were manufactured in Vietnam and distributed nationwide by The Mentholatum Company.
The recent FDA recall includes several popular Rohto products, including:
The food and drugs regulatory body has warned consumers to stop using the recalled eye drops immediately and check the FDA’s recall notice for affected lot numbers and expiration dates.
Also read: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know
Unlike tablets or capsules, eye drops are applied directly onto the eye. The process has limited natural protection against harmful microorganisms.
When sterility cannot always be guaranteed, bacteria or fungi may contaminate the solution easily.
Using contaminated eye drops significantly increases the risk of eye irritation, painful infections, damage to the corneas and, in extreme cases, vision loss.
Although the FDA has not disclosed any confirmed adverse effects linked to this recall, it said the products were withdrawn from the market as a precaution because ophthalmic products must strictly remain sterile throughout their shelf life.
The agency classified the recall as Class II, meaning exposure could cause temporary or reversible health effects, while serious harm is mostly unlikely.
Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer
Commenting on previous FDA recalls, Dr Gary Novack, clinical professor in the Department of Ophthalmology and Vision Science at UC Davis, said, “For eye drops, that means strict sterility, ensuring products are free from microorganisms like bacteria.”
He also said that manufacturing facilities must maintain contamination-free conditions because medicines used in the eye bypass many of the body’s natural defence mechanisms.
Dr Jeffrey H. Ma, ophthalmologist at the UC Davis Eye Center, also advised patients not to use recalled products: “Drops that are not on the recall list should be safe to use. If you have any of the drops on the list, you should immediately throw them away.”
Health authorities recommend that people:
The latest recall comes after multiple eye drop recalls in recent years linked to manufacturing and sterility issues, highlighting growing scrutiny of ophthalmic products.
Credit: AP
US President is reportedly asking Secretary of the US Department of Health and Human Services Robert F. Kennedy Jr to make more efforts to cut childhood vaccines in America, according to a media report.
The 80-year-old US president hopes to make “alleviating autism” a component of his legacy, and told Kennedy that he wasn’t making enough cuts to the US vaccination schedule, the Wall Street Journal reported. The report, citing sources, said that Trump believes cutting down the number of recommended childhood vaccines may lead to a drop in autism rates in the country.
He, thus, expressed frustration with the slow pace of progress on the issue at a mid-June Oval Office meeting with Kennedy.
“Donald Trump has been anti-vaccine at least since 2015,” said Paul Offit, director of the Vaccine Education Center and an infectious diseases physician at Children’s Hospital of Philadelphia. At the Republican primary debate that year, Trump said that autism had gotten “totally out of control” and vaccines should be in “smaller doses over a longer period of time”.
Further, Trump reportedly also wants to break the combination vaccine for the measles, mumps, and rubella vaccination (MMR) into different shots, to reduce the risk of autism.
However, there has been no scientific evidence to prove that paring down the childhood vaccine schedule can reduce autism rates. Similarly, studies over the years have shown no connection between the MMR and autism.
Kennedy, last year, cancelled roughly $500 million in mRNA vaccine research grants and removed every single member of an immunization advisory panel.
But after White House aides told Kennedy that vaccine skepticism was less popular with voters, and they asked him to focus on more palatable topics, such as food reform, the Health Secretary has largely been mum on vaccines publicly. Trump’s recent urgency on the issue ignores his political advisers’ warnings.
Meanwhile, the US Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines is reigniting the debate over how health agencies should communicate scientific evidence.
The controversy was sparked by changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.
The page also says the HHS is continuing to investigate the causes of autism.
The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.
Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.
The changes have also drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.
Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed. Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.
Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.
Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.
The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.
For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.
Credit: AI
A new study suggests that nearly one in three adults in the United States could benefit from blood pressure-lowering medication under the latest treatment guidelines.
Yet millions who qualify are either not taking medication or have blood pressure that remains above recommended targets, highlighting a major gap in hypertension care.
The findings, published in JAMA, analysed data from the U.S. National Health and Nutrition Examination Survey (NHANES) collected between 2021 and 2023.
Researchers evaluated how the updated 2025 American Heart Association (AHA) and American College of Cardiology (ACC) blood pressure guidelines would affect treatment eligibility.
According to the researchers, an estimated 34 million U.S. adults, roughly one in three, meet the criteria for blood pressure medication but are not currently taking it.
Nearly 19 million of them have blood pressure readings of 140/90 mmHg or higher, placing them at increased risk of heart attack, stroke, kidney disease, and dementia if left untreated.
The study also found that almost 80% of adults with hypertension have blood pressure levels above the recommended treatment goal of less than 130/80 mmHg.
Also read: Not Just The Heart, Obesity In Midlife Could Be Just As Harmful To The Brain: Study
Researchers observed that many adults with high blood pressure were not taking any antihypertensive medication, despite being eligible under current guidelines.
Among those who were not receiving treatment, about two-thirds had blood pressure values within 10 mmHg of the recommended target.
The observation suggested that a combination of medication and lifestyle changes could help many get their readings down.
On the other hand, people who were already taking medication often had blood pressure levels that remained well above target, indicating that medication may need to be intensified.
The authors wrote, “Many could potentially achieve blood pressure control with initiation of antihypertensive medication and lifestyle modification.”
They further noted, “These findings highlight a large gap in hypertension control that implementation of the 2025 AHA/ACC blood pressure guideline recommendations could address.”
High blood pressure is often called the “silent killer” because it usually causes no symptoms while quietly damaging blood vessels and vital organs over time.
According to the U.S. Centers for Disease Control and Prevention (CDC), uncontrolled hypertension is a major contributor to heart disease and stroke, two of the leading causes of death in the country.
Researchers also pointed out that more than 80% of adults with uncontrolled blood pressure had health insurance and a regular place for medical care, suggesting that access alone does not fully explain why treatment goals are not being met.
The updated AHA/ACC guidelines emphasise that treatment should not rely on medication alone. Doctors recommend:
As hypertension continues to affect millions, researchers say earlier diagnosis, timely treatment, and sustained lifestyle changes could substantially reduce the burden of cardiovascular disease and improve long-term health outcomes.
© 2024 Bennett, Coleman & Company Limited